CA29383X1033
© PR Newswire
19.12.2025
ENBI
LISTED
CSE
Canadian Investment Regulatory Organization Trading Halt - ENBI
News Preview
VANCOUVER, BC, Dec. 19, 2025 /CNW/ - The following issues have been halted by CIRO:
Company: Entheon Biomedical Corp.CSE Symbol: ENBIAll Issues: YesReason: Pending NewsHalt Time (ET): 8:48 AMCIRO can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensur...
Themefolio
Profiler
Peergroup
© Newsfile
11.07.2022
ENBI
LISTED
CSE
Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news release dated June 7, 2022, it has completed the sale of its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to Cybin IRL Limited (the "...
Themefolio
Profiler
Peergroup
© Newsfile
07.06.2022
ENBI
LISTED
CSE
Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to w...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Newsfile
05.04.2022
ENBI
LISTED
CSE
Entheon Biomedical Announces Non-Brokered Private Placement Financing
News Preview
Vancouver, British Columbia--(Newsfile Corp. - April 5, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announces that it is pro...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Newsfile
29.03.2022
ENBI
LISTED
CSE
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel & New Clinical Research Platform
News Preview
Improved Genetic Screening Platform to Strengthen Entheon's Psychedelic-Assisted ProtocolsVancouver, British Columbia--(Newsfile Corp. - March 29, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge bi...
Themefolio
Profiler
Peergroup
© Newsfile
15.03.2022
ENBI
LISTED
CSE
Entheon Biomedical Announces Enrollment in Phase 1 Study of DMT
News Preview
Vancouver, British Columbia--(Newsfile Corp. - March 15, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, today announced that th...
Themefolio
Profiler
Peergroup
© Newsfile
24.02.2022
ENBI
LISTED
CSE
Entheon Biomedical Announces EBIQ-101 First-Patient Dose
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 24, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provid...
Themefolio
Profiler
Peergroup
© Newsfile
16.02.2022
ENBI
LISTED
CSE
Entheon Biomedical Partners with Wavepaths on Upcoming Observational Study
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is launching the upcoming EBIQ-...
Themefolio
Profiler
Peergroup
© Newsfile
03.02.2022
ENBI
LISTED
CSE
Entheon Biomedical Announces the Approval of DMT Clinical Trial
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 3, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, announced today the a...
Themefolio
Profiler
Peergroup
© Newsfile
18.01.2022
ENBI
LISTED
CSE
Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today
News Preview
Expanding brand awareness and access to HaluGen's Psychedelics Genetic Test KitVancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers...
Themefolio
Profiler
Peergroup
© Newsfile
18.01.2022
ENBI
LISTED
CSE
Entheon Biomedical Corp. Files Preliminary Shelf Prospectus
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") announced that it has filed a preliminary short form base shelf prospectus dated January 14, 2022 (the "Preliminary Prospectus") with the securities commissions in each of the provinces and...
Themefolio
Profiler
Peergroup
© Newsfile
06.01.2022
ENBI
LISTED
CSE
Entheon Biomedical Provides Update on DMT Human Trial and Announces Regulatory Submission to Ethics Committee
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 6, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, has announced the subm...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Newsfile
21.12.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces Expanded Psychedelics Genetic Test Panel
News Preview
Subsidiary HaluGen Life Sciences has expanded its genetic test panel to include the CYP2D6 gene, a marker indicating the metabolism of LSD, MDMA and ayahuascaVancouver, British Columbia--(Newsfile Corp. - December 21, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused o...
Themefolio
Profiler
Peergroup
© Newsfile
16.12.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces EEG Patent Application & Provides Research Update
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to provid...
Themefolio
Profiler
Peergroup
© Newsfile
04.12.2021
ENBI
LISTED
CSE
Entheon to Participate in the H.C. Wainwright 2nd Annual Psychedelics Conference on December 6, 2021
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announc...
Themefolio
Profiler
Peergroup
© Newsfile
01.12.2021
ENBI
LISTED
CSE
Psychiatrist and Addiction Researcher, Dr. Henry Kranzler Joins Entheon Advisory Board
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biomedical company focused on the research and development of psychedelic drugs and leading-edge biomarkers to provide personalized treatment of addiction disorders, is pleased to announc...
Themefolio
Profiler
Peergroup
© Newsfile
24.11.2021
ENBI
LISTED
CSE
Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs
News Preview
Shipment of GMP DMT, In Vitro HERG and Genotox Assays Completed, and In Vivo Toxicity Assays UnderwayVancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction,...
Themefolio
Profiler
Peergroup
© Newsfile
10.11.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study
News Preview
Entheon ID(TM) Clinical Study to Assess the Effect of Ketamine on Neurological Activity as Measured by EEGVancouver, British Columbia--(Newsfile Corp. - November 10, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addic...
Themefolio
Profiler
Peergroup
© Newsfile
27.10.2021
ENBI
LISTED
CSE
Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials
News Preview
Vancouver, British Columbia--(Newsfile Corp. - October 27, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to provide an update on its operations and progress on its strategic initiatives.Observati...
Themefolio
Profiler
Peergroup
© Newsfile
25.08.2021
ENBI
LISTED
CSE
Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board
News Preview
Dr. David Erritzoe to provide guidance on psychopharmacological researchVancouver, British Columbia--(Newsfile Corp. - August 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that Dr...
Themefolio
Profiler
Peergroup
© Newsfile
24.08.2021
ENBI
LISTED
CSE
Entheon Biomedical Corp. Announces DTC Eligibility
News Preview
Vancouver, British Columbia--(Newsfile Corp. - August 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its common shares are now eligible for electronic clearing and settlement...
Themefolio
Profiler
Peergroup
© Newsfile
12.08.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine
News Preview
EEG Study to be incorporated into Entheon IQ(TM), developing data-driven treatment algorithms for psychedelic treatmentsVancouver, British Columbia--(Newsfile Corp. - August 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to...
Themefolio
Profiler
Peergroup
© Newsfile
30.07.2021
ENBI
LISTED
CSE
Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
News Preview
Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted ProtocolsVancouver, British Columbia--(Newsfile Corp. - July 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. ("Lo...
Themefolio
Profiler
Peergroup
© Newsfile
28.07.2021
ENBI
LISTED
CSE
Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw
News Preview
Vancouver, British Columbia--(Newsfile Corp. - July 28, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neurosci...
Themefolio
Profiler
Peergroup
© Newsfile
30.06.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 30, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of emergency physician and addiction specialist, Dr. Dinesh Bayana a...
Themefolio
Profiler
Peergroup
© Newsfile
25.06.2021
ENBI
LISTED
CSE
Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit Awareness
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 25, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agreement with Maya health PBC ("Maya'') to help drive brand awareness of the Company's...
Themefolio
Profiler
Peergroup
© Newsfile
22.06.2021
ENBI
LISTED
CSE
Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave
News Preview
To drive brand awareness of, and access to, HaluGen's Psychedelics Genetic Test KitVancouver, British Columbia--(Newsfile Corp. - June 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, has announced an agre...
Themefolio
Profiler
Peergroup
© Newsfile
17.06.2021
ENBI
LISTED
CSE
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences and Silo Wellness Announces Psychedelics Genetic Test Kit Partnership
News Preview
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon"), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) ("Silo Wellness"), a functional and psilocybin mushroom compan...
Themefolio
Profiler
Peergroup
© Newsfile
16.06.2021
ENBI
LISTED
CSE
Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.
News Preview
Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted ProtocolsVancouver, British Columbia--(Newsfile Corp. - June 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company has entered into a definitive agreement dated June...
Themefolio
Profiler
Peergroup
© Newsfile
10.06.2021
ENBI
LISTED
CSE
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US
News Preview
HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapyVancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic...
Themefolio
Profiler
Peergroup
© Newsfile
18.05.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 18, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Laboratorium Ofichem BV ("Of...
Themefolio
Profiler
Peergroup
© Newsfile
14.05.2021
ENBI
LISTED
CSE
Entheon Biomedical Corp. Provides Corporate Update
News Preview
Launch of Psychedelics DNA Test KitPhase 1 clinical trial for DMT progressing as plannedPre-clinical In Vivo work scheduled to start at Israeli CROStrengthened expertise focused on driving initiatives forwardUpgraded OTC Listing Financial UpdateVancouver, British Columbia--(Newsfile Corp. - May 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE:...
Themefolio
Profiler
Peergroup
© Newsfile
05.05.2021
ENBI
LISTED
CSE
Entheon Biomedical Lists on OTCQB Venture Market
News Preview
Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: "1XU1") ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been approved for trading on the OTCQB Venture Market ("OTCQB") effec...
Themefolio
Profiler
Peergroup
© Newsfile
06.04.2021
ENBI
LISTED
CSE
Entheon Biomedical Corp. Launches HaluGen's Psychedelics Genetic Test
News Preview
HaluGen's DNA genetic testing provides insights into the sensitivity and risks associated with psychedelic-assisted psychotherapyVancouver, British Columbia--(Newsfile Corp. - April 6, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat a...
Themefolio
Profiler
Peergroup
© Newsfile
03.03.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces Nancy Maher, Special Advisor of Data Science and Regulatory Affairs
News Preview
Senior Pharmaceutical & Technology Executive and Current SVP, Chief Information Officer, North America at Kyowa Kirin International plc., Previously of IBM, Schering-Plough, Merck and Gilead Joins Entheon's Advisory BoardVancouver, British Columbia--(Newsfile Corp. - March 3, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE...
Themefolio
Profiler
Peergroup
© Newsfile
24.02.2021
ENBI
LISTED
CSE
Entheon Biomedical Corp. Provides Update on Subsidiary, HaluGen Life Sciences
News Preview
Completion of research and development phase for HaluGen's Psychedelics Genetic TestVancouver, British Columbia--(Newsfile Corp. - February 24, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides a production update on...
Themefolio
Profiler
Peergroup
© Newsfile
22.02.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces Ethics Approval for In Vivo DMT Study
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced ethics approval for an upcoming pre-clinical study to be conducted by the clinical research...
Themefolio
Profiler
Peergroup
© Newsfile
16.02.2021
ENBI
LISTED
CSE
Entheon Biomedical Hires Chief Business Officer; Senior Pharma Executive Dr. Brian Jahns to Oversee Business Development
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Dr. Brian Jahns to the role of Chief Business Officer.D...
Themefolio
Profiler
Peergroup
© Newsfile
04.02.2021
ENBI
LISTED
CSE
Entheon Biomedical Hires ClearTV Executive as VP of Digital Experience Entertainment Veteran Jonna Birgans to Oversee Digital and VR Content Development
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC PINK: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the appointment of Jonna Birgans, a highly experienced media executive and...
Themefolio
Profiler
Peergroup
© Newsfile
02.02.2021
ENBI
LISTED
CSE
Entheon Biomedical Provides Update on Centre for Human Drug Research License Amendments
News Preview
Vancouver, British Columbia--(Newsfile Corp. - February 2, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, provides an update on license amendments issued to its clinical research organization,...
Themefolio
Profiler
Peergroup
© Newsfile
22.01.2021
ENBI
LISTED
CSE
Entheon Biomedical to be Included in First North American Psychedelic ETF
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the firs...
Themefolio
Profiler
Peergroup
© Newsfile
19.01.2021
ENBI
LISTED
CSE
Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 19, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) (OTC Pink: ENTBF) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced a partnership with Divergence Neuro Technologies Inc. ("Divergence"), a company fo...
Themefolio
Profiler
Peergroup
© Newsfile
14.01.2021
ENBI
LISTED
CSE
Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.
News Preview
Genetic Screening Test Technology and Data to Strengthen Entheon's Psychedelic-Assisted ProtocolsVancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. ("HaluGen")...
Themefolio
Profiler
Peergroup
© Newsfile
12.01.2021
ENBI
LISTED
CSE
Entheon Biomedical Engages Star Finance GmbH for Investor Relations
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 12, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces that it has entered into a consulting agreement (the "Agreement") with Star...
Themefolio
Profiler
Peergroup
© Newsfile
11.01.2021
ENBI
LISTED
CSE
Entheon Biomedical Engages World Renowned Media Personality DJ Skee, AKA Scott Keeney, as Media Advisor
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has engaged Mr. Scott Keeney, to serve as a media advisor. In his role, Mr. Keeney wi...
Themefolio
Profiler
Peergroup
© Newsfile
04.01.2021
ENBI
LISTED
CSE
Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC ("Heading Health"), a p...
Themefolio
Profiler
Peergroup
© Newsfile
25.12.2020
ENBI
LISTED
CSE
Entheon Biomedical Closes Private Placement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 25, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it has closed a non-brokered private placement financing for total gross proceeds of CAD $3,174,374.25 (the "Placement"). The majority of the Placement was subscribed for by strategic inve...
Themefolio
Profiler
Peergroup
© Newsfile
18.12.2020
ENBI
LISTED
CSE
Entheon Biomedical Announces Private Placement
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 18, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it is proceeding with a fully allocated, non-brokered private placement financing of 4,266,997 Units (the "Units") at a price of CDN$0.75 per Unit for gross proceeds of CDN$3,200,247....
Themefolio
Profiler
Peergroup
© Newsfile
09.12.2020
ENBI
LISTED
CSE
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 9, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Psygen Labs Inc. ("Psygen"). Under the...
Themefolio
Profiler
Peergroup
© Newsfile
04.12.2020
ENBI
LISTED
CSE
Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. ("Wonder Scientific").Wonder Scientific's team of Univers...
Themefolio
Profiler
Peergroup
© Newsfile
01.12.2020
ENBI
LISTED
CSE
Entheon Biomedical Announces CRO Agreement with CHDR for Phase 1 Clinical Trial; Centre for Human Drug Research Led DMT Study to Start in 2021
News Preview
Vancouver, British Columbia--(Newsfile Corp. - December 1, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a Clinical Study Agreement with the Contract Research Organization (CRO) Centre for H...
Themefolio
Profiler
Peergroup
© Newsfile
26.11.2020
ENBI
LISTED
CSE
Entheon Biomedical to Begin Trading on the Frankfurt Exchange
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 26, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that its shares have commenced trading on the Frankfurt Stock Exchange under the symbo...
Themefolio
Profiler
Peergroup
© Newsfile
13.11.2020
ENBI
LISTED
CSE
Eric Sprott Announces Holdings in Entheon Biomedical Corp. (formerly, MPV Exploration Inc.)
News Preview
Toronto, Ontario--(Newsfile Corp. - November 12, 2020) - Eric Sprott announces that he beneficially owns and controls 3,200,000 common shares (shares) and 1,100,000 share purchase warrants (warrants) of Entheon Biomedical Corp., representing approximately 7.9% on a non-diluted basis of the outstanding shares and 10.4% on a partially diluted basis,...
Themefolio
Profiler
Peergroup
© Newsfile
12.11.2020
ENBI
LISTED
CSE
Entheon Biomedical Corp. Commences Trading on the Canadian Securities Exchange
News Preview
Vancouver, British Columbia--(Newsfile Corp. - November 12, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (formerly, MPV Exploration Inc.) ("Entheon" or the "Company") is pleased to announce that, further to its news release dated November 5, 2020, the Company has commenced trading on the Canadian Securities Exchange ("CSE") under the symbol "ENBI"....
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
